Randomized studies comparing RD or VD plus a newer agent vs RD or VD alone
| Agent . | Trial (reference) . | No. of patients . | Inclusion criteria . | RR, % . | CR rate, % . | Median PFS, mo . | Median OS, mo . | Median follow-up, mo . |
|---|---|---|---|---|---|---|---|---|
| Lenalidomide-based studies | ||||||||
| Carfilzomib (KRd vs Rd) | Aspire (56) | 792 | 1-3 previous lines of therapy | 87 vs 66.7 | 31.8 vs 9.3 | 26 vs 17.6 | 2-y 73% vs 65% | 32 |
| P < .001 | P < .001 | P = .0001 | P = .004 | |||||
| HR, 0.69 | HR, 0.79 | |||||||
| Elotuzumab (ERd vs Rd) | Eloquent (57) | 646 | 1-3 previous lines of therapy | 79 vs 66 | 11 vs 11 | 19.4 vs 14.9 | 30% deaths vs 37% | 24.5 |
| HR, 0.70 | ||||||||
| Ixazomib (IRd vs Rd) | Tourmaline (58) | 722 | 1-3 prior lines of therapy | 78 vs 72 | CR + VGPR | 20.6 vs 14.7 | NA | 14.7 |
| Len and Bort-refractory excluded | 48 vs 39 | P = .01 | ||||||
| HR, 0.74 | ||||||||
| Daratumumab (DaRd vs Rd) | Pollux (59) | 569 | 1 or more lines of therapy | 92.9 vs 76.4 | 43.1 vs 19.2 | 6-mo PFS | NA | 13.5 |
| Len-refractory excluded | 83.2% vs 60.1% | |||||||
| P < .001 | ||||||||
| HR, 0.37 | ||||||||
| Bortezomib-based studies | ||||||||
| Panobinostat (PVD vs VD) | Panorama 1 (60, 61) | 768 | 1-3 previous lines of therapy | 60.7 vs 56.6 | CR + n-CR, 27.6 vs 15.7 | 11.9 vs 8 | 40.3 vs 35.8 | 6.5 |
| P = .009 | P < .0001 | P = .54 | ||||||
| HR, 0.63 | HR, 0.94 | |||||||
| Elotuzumab (EVD vs VD) | (62) | 152 | 1-3 previous lines of therapy | 66 vs 63 | CR + VGPR, 37 vs 26 | 9.7 vs 6.9 | 2-y OS, 73% vs 66% | 15.9 |
| Bort-refractory excluded | P = .09 | |||||||
| HR, 0.72 | ||||||||
| Daratumumab (DaVD vs VD) | Castor (63) | 498 | >1 previous lines of therapy | 82.9 vs 63.2 | 19.2 vs 9 | NR vs 7.2 mo | 31 deaths vs 49 | 7.4 |
| Bort-refractory excluded | P < .001 | HR, 0.77 | ||||||
| HR, 0.39 |
| Agent . | Trial (reference) . | No. of patients . | Inclusion criteria . | RR, % . | CR rate, % . | Median PFS, mo . | Median OS, mo . | Median follow-up, mo . |
|---|---|---|---|---|---|---|---|---|
| Lenalidomide-based studies | ||||||||
| Carfilzomib (KRd vs Rd) | Aspire (56) | 792 | 1-3 previous lines of therapy | 87 vs 66.7 | 31.8 vs 9.3 | 26 vs 17.6 | 2-y 73% vs 65% | 32 |
| P < .001 | P < .001 | P = .0001 | P = .004 | |||||
| HR, 0.69 | HR, 0.79 | |||||||
| Elotuzumab (ERd vs Rd) | Eloquent (57) | 646 | 1-3 previous lines of therapy | 79 vs 66 | 11 vs 11 | 19.4 vs 14.9 | 30% deaths vs 37% | 24.5 |
| HR, 0.70 | ||||||||
| Ixazomib (IRd vs Rd) | Tourmaline (58) | 722 | 1-3 prior lines of therapy | 78 vs 72 | CR + VGPR | 20.6 vs 14.7 | NA | 14.7 |
| Len and Bort-refractory excluded | 48 vs 39 | P = .01 | ||||||
| HR, 0.74 | ||||||||
| Daratumumab (DaRd vs Rd) | Pollux (59) | 569 | 1 or more lines of therapy | 92.9 vs 76.4 | 43.1 vs 19.2 | 6-mo PFS | NA | 13.5 |
| Len-refractory excluded | 83.2% vs 60.1% | |||||||
| P < .001 | ||||||||
| HR, 0.37 | ||||||||
| Bortezomib-based studies | ||||||||
| Panobinostat (PVD vs VD) | Panorama 1 (60, 61) | 768 | 1-3 previous lines of therapy | 60.7 vs 56.6 | CR + n-CR, 27.6 vs 15.7 | 11.9 vs 8 | 40.3 vs 35.8 | 6.5 |
| P = .009 | P < .0001 | P = .54 | ||||||
| HR, 0.63 | HR, 0.94 | |||||||
| Elotuzumab (EVD vs VD) | (62) | 152 | 1-3 previous lines of therapy | 66 vs 63 | CR + VGPR, 37 vs 26 | 9.7 vs 6.9 | 2-y OS, 73% vs 66% | 15.9 |
| Bort-refractory excluded | P = .09 | |||||||
| HR, 0.72 | ||||||||
| Daratumumab (DaVD vs VD) | Castor (63) | 498 | >1 previous lines of therapy | 82.9 vs 63.2 | 19.2 vs 9 | NR vs 7.2 mo | 31 deaths vs 49 | 7.4 |
| Bort-refractory excluded | P < .001 | HR, 0.77 | ||||||
| HR, 0.39 |
D, dexamethasone; d, low-dose dexamethasone; Da, daratumumab; E, elotuzumab; I, ixazomib; K, carfilzomib; NA, not assessed; n-CR, near-complete response; P, panobinostat; R, lenalidomide; RR, response rate; V, velcade (bortezomib). Other abbreviations are explained in Tables 1-3.